No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.

Laszlo HegedüsSteven I ShermanR Michael TuttleBernt J von ScholtenSøren RasmussenJulie D KarsbølGilbert H Danielsnull null

Published in: Diabetes care (2017)

There was no evidence of a difference in calcitonin concentrations between the liraglutide and placebo groups, and no C-cell malignancies occurred in the liraglutide group.

Keyphrases

single cell
cell therapy
phase iii
clinical trial
stem cells
randomized controlled trial
phase ii